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Risk factors for liposomal bupivacaine
resistance after total hip or knee
arthroplasties: a retrospective observational
cohort in 237 patients
Scott Buzin1, Arianna L. Gianakos1, Deborah Li2, Anthony Viola3, Sherif Elkattawy1, David M. Keller1,
Richard S. Yoon1* and Frank A. Liporace1
Abstract
Purpose: Liposomal bupivacaine demonstrated promise decreasing postoperative pain in total hip and total knee
arthroplasty (THA/TKA). Some randomized trials have shown non-superior results; however, confounding variables
were not accounted for in such analyses. This study attempts to determine risk factors associated with failure of
pain management in patients receiving liposomal bupivacaine.
Methods: Postoperative pain scores were collected following primary or revision arthroplasties between January
2016 and December 2017. Retrospective analysis of institutional total joint quality and outcomes registry was
screened and patients undergoing primary or revision arthroplasties who completed a multi-modal pain
management including liposomal bupivacaine were included in the study. Patients with a history of infection/
deviated from the institutional pain management protocol were excluded.
Results: A total of 237 patients were included for analysis. Younger patients less than 64 years old had significantly
higher pain scores between 0 and 12 h and > 24 h. Active smokers had significantly higher pain scores between 0 and 6
h and > 24 h. Patients with a history of opioid use/pain management had significantly higher pain scores at 6-12 h and
24-48 h. Regression analysis indicated risk factors for resistance to liposomal bupivacaine are younger patients less than
64 years old, those undergoing primary THA, and patients with a history of smoking/pain management/opioid use.
Conclusion: We identify risk factors for resistance to liposomal bupivacaine, which include younger age less than 64 years
old, history of smoking/pain management/opioid use. Future studies should use these risk factors as exclusion criteria
when using liposomal bupivacaine or initiating any randomized trials regarding efficacy.
Keywords: Liposomal bupivacaine, Total hip arthroplasty, Total knee arthroplasty, Pain management
Introduction
Control of postoperative pain in the setting of primary
total hip and total knee arthroplasty (THA/TKA) is critical
for successful outcomes leading to quicker recovery, re-
duced readmission rates, and lower treatment costs [1].
Currently, multi-modal pain protocols are the standard
for postoperative pain control following THA/TKA [2–5].
Recently, liposomal bupivacaine gained popularity due to
its extended release and initial, promising results [6].
However, not long after popularity grew, a few random-
ized trials reported data noting non-superior results when
comparing liposomal bupivacaine to other pain modalities
(within an operating multi-modal pain protocol) [7–10].
While most of the bias was removed with these level 1
trials, these studies, along with its predecessors, do not in-
clude subset analyses that may provide more insight into
pain control failure [11]. In this observational regression
analysis, a single-surgeon, consecutive cohort is analyzed
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to identify any significant risk factors for liposomal bupi-
vacaine resistance.
Methods
Institutional Review Board (IRB) approval, study number
20171537, was obtained to collect patient outcome data
following THA and TKA at our institution. A single sur-
geon, consecutive cohort of 286 consecutive patients
undergoing either THA or TKA between January 2016
and December 2017 were retrospectively reviewed. Retro-
spective analysis of institutional total joint quality and out-
comes registry was screened for inclusion. Inclusion
criteria consisted of any patient undergoing primary or
revision arthroplasties with completed multi-modal pain
management strategy and received liposomal bupivacaine
(Table 1). Exclusion criteria were those undergoing any
THA or TKA in the setting or past history of infection or
those who were unable to receive liposomal bupivacaine
(i.e. allergy).
The standardized pain management protocol in-
cluded a multi-modal approach focusing on both pre-
operative and postoperative pain control (Table 1). As
part of a multimodal pain control regimen, liposomal
bupivacaine was administered after final implants were
placed prior to closure. Twenty cc of liposomal bupi-
vacaine was diluted with 40 cc of normal saline for a
total administration dose of 60 cc. Another injection is
given within the surgical site consisting of 0.5% bupi-
vacaine, morphine, and ketorolac. A 30 cc mixture of
equal parts bupivacaine, morphine, and ketorolac were
injected systematically into the periosteum, joint capsule,
and subcutaneous tissue using an 18-guage needle. The
determination of which patients would receive blocks
and/or patient controlled analgesia (PCA) were at the dis-
cretion of the surgeon and anesthesiologist taking care of
the patient.
As per institutional standard post-anesthesia care unit
(PACU) and orthopaedic floor nursing protocol, pain
scores were assessed and recorded via the Wong-Baker
Visual Analog scale (VAS). Timepoints included times at
2, 4, 6, 8, 12, 24, and 48 h post-operatively.
Statistical analysis
Frequencies and proportions of categorical patient
demographic and surgical variables are reported. Means
and standard deviations (SD) of continuous patient
demographics and pain score variables are reported. To
test for differences in demographic and surgical variables
based on pain failure at 0–6, 6–12, 12–24, and 24–48 h
time intervals, chi-square tests were calculated for cat-
egorical variables and one-way ANOVA tests were calcu-
lated for continuous variables. Fischer-Exact tests were
used in place of chi-square tests to obtain p-values where
> 25% of cells have expected counts < 5. The main out-
come measured was highest pain score (0–10) recorded
within a 48 h window post-op. The relationship between
patient demographics and surgical variables with highest
post-op pain score was assessed with absolute differences
(AD) and 95% confidence intervals (95% CI) using bivari-
ate and multivariable linear regression analysis. Variables
with a p-value < 0.05 from the bivariate analysis were in-
cluded in the multivariable model. A p-value of < 0.05 was
considered to be statistically significant in all calculations.
All statistical analysis was performed using SAS 9.4 (SAS
Institute Inc., Cary, NC).
Results
A total of 237 patients were included in the cohort for
analysis. The average age at surgery was 62.8 years, aver-
age BMI was 32.4 kg/m2, and 155 (68.6%) patients were
female. Surgery was performed in the right lower extrem-
ity in 133 (58.3%) patients with a primary total knee mak-
ing up a majority of the procedures (54.7%), followed by
primary total hip (29.6%), then revision total knee (8.1%),
revision total hip (6.7%) and bilateral knee (0.9%). A ma-
jority of patients did not receive PCA (78.7%). Spinal/epi-
dural blocks were administered to 26 (11.3%) patients,
femoral/intraarticular blocks to 11 (4.8%) patients, and
193 (83.9%) received no blocks. A total of 47 (21.0%) of
patients were current/former smokers, and 42 (18.7%)
used alcohol. Patients with a history of pain management
made up 41.8% of the population, and 42.5% of patients
took pain medication at home (31% opioids, 4.0% Neuron-
tin/Lyrica, 7.5% other). A total of 21 (9.3%) of patients
Table 1 Pain control protocol for total joint arthroplasty
Preoperative Postoperative
Inpatient On discharge
Celecoxib PO - 200 mg
Pregabalin PO - 50mg (<65yo), 25 mg (>65yo)
Acetaminophen IV – 1000mg once
Celecoxib PO - 200 mg daily
Pregabalin PO - 50mg BID (<65yo)
MS Contin PO – 15mg BID (<65yo)
Acetaminophen IV – 1000 mg q8h (1st 24 h)
Acetaminophen PO – 650mg q6h (> 24 h)
Oxycodone PO – 5 mg q4h PRN pain 1–3
Oxycodone PO – 10 mg q4h PRN pain 4–6
Morphine IV – 2 mg q4h PRN pain 7–10
Patient-controlled analgesiaa
Percocet PO - 5/325 mg q4-6h PRN
Celecoxib PO - 200 mg daily (2 weeks)
Pregabalin PO - 50 mg BID (<65yo) (2 weeks)
MS Contin PO – 15 mg BID (<65yo) (2 weeks)
apatient-controlled anesthesia was provided at the discretion of the anesthesia department and was not offered to all patients
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were taking steroids and 23 (10.1%) taking antidepressants
at the time of surgery. Diabetics made up 29.7% of the
population (Table 2).
Demographic and surgical characteristics of patients who
experienced pain failure at 0-6 h, 6-12 h, 12-24 h, and 24-48 h
intervals post-Op
Pain scores were measured at 0–6 h, 6–12 h, 12–24 h, and
24–48 h intervals post-op and recorded as the highest pain
score within that time interval. A pain score of ≥5 was
considered to be pain failure while a pain score < 5 was
considered to be adequately controlled pain. A total of 91
(38.4%) patients experienced pain failure at 0–6 h post-op,
65 (35.7%) patients at 6–12 h post-op, 147 (71.4%) patients
at 12–24 h post-op, and 171 (79.5%) patients at 24–48 h
post-op. Mean highest pain score was 1.8 ± 1.8 in the
PACU, 4.3 ± 3.1 at 0–6 h post-op, 4.2 ± 3.1 at 6–12 h post-
op, 6.4 ± 2.8 at 12–24 h post-op, and 6.8 ± 2.6 at 24–48 h
post-op. Overall, within the first 48 h post-op, mean high-
est pain score was 7.5 ± 2.2 and a total of 205 (86.5%) of
patients experienced pain failure at least once (Table 3).
Overall, younger patients less than 64 years old,
smokers, and patients with a history of pain manage-
ment had a higher rate of pain failure within the first 48
h post-op (Table 2). Patients who were younger than 64
years old at the time of surgery had a higher proportion
of pain failure at 0–6 h (60.0 yrs. vs. 64.6 yrs.; p = 0.002),
6–12 h (63.5 yrs. vs. 71.1 yrs.; p = 0.004), and 24–48 h
(61.8 yrs. vs. 66.5 yrs.; p = 0.01) intervals. Among patients
with a history of pain management, a higher proportion
of patients had pain failure at 6–12 h (61.3% pain score ≥
5 vs. 33.3% pain score < 5; p-value = 0.0003) and 24–48
h (48.2% pain score ≥ 5 vs. 26.2% pain score < 5; p =
value = 0.01) intervals. A higher proportion of pain fail-
ure was also observed in patients who were on opioid
pain medication at home at 6–12 h (50.8% pain score ≥ 5
vs. 23.7% pain score < 5; p-value = 0.001) and 24–48 h
(38.2% pain score ≥ 5 vs. 11.9% pain score < 5; p-value =
0.004) intervals. Patients who were not on any pain
medication at home were less likely to experience pain
failure at 6–12 h (66.7% pain score < 5 vs. 38.1% pain
score ≥ 5; p-value = 0.001) and 24–48 h (73.8% pain
score < 5 vs. 50.9% pain score ≥ 5; p-value = 0.004) inter-
vals. A higher proportion of smokers experienced pain
failure within the first 0-6 h postop (28.2% pain score ≥ 5
vs. 16.6% pain score < 5; p-value = 0.04) and patients
who received PCA after surgery experienced a higher
rate of pain failure 12–24 h after surgery (83.3% pain
score ≥ 5 vs. 69.1% pain score < 5; p-value = 0.03). Gen-
der, BMI, side of surgery, type of surgery, type of block
received, alcohol usage, steroid usage, antidepressant
usage, and prior diagnosis of diabetes were not signifi-
cantly associated with pain failure at any time interval 0-
48 h after surgery (p-value> 0.05) (Table 2).
Bivariate and multivariable linear regression of highest
pain score recorded within 48 h post-Op
Linear regression models were constructed with the
highest pain score recorded within the first 48 h post-op
as the main outcome measure (Table 4). In bivariate
analysis, older patients over 64 years old had lower pain
score (AD -0.05; 95% CI -0.07, 0.02) and patients with a
higher BMI had a higher pain score (AD 0.03; 95% CI
0.01, 0.05). Primary THA was associated with a lower
pain score compared to primary TKA (AD -0.83; 95% CI
-1.48, − 0.19) and patients who received PCA after sur-
gery had a higher pain score compared to those who did
not (AD 0.70; 95% CI 0.01, 1.39). Patients who had a his-
tory of pain management had a higher pain score com-
pared to those who had no history of pain management
(AD 0.69; 95% CI 0.12, 1.27) and patients who used opioid
pain medications at home had a higher pain score by 1
point compared to those who did not use any pain medi-
cations at home (AD 0.97; 95% CI 0.34, 1.59) (Table 3).
Patients who underwent spinal nerve blocks were not
found to have statistically significant better pain control
when compared to those who had general anesthesia (AD
0.69; 95% CI -0.20, 1.59). Similar results were found when
peripheral nerve blocks were compared with those pa-
tients who underwent general anesthesia (AD 0.94; 95%
CI -0.39, 2.27).
In multivariable analysis, age and primary total hip
procedure were both negatively associated with higher
pain scores. Older patients greater than 64 years old
scored lower on pain compared to younger patients (AD
-0.05; 95% CI -0.07, − 0.02) and primary total hip pro-
cedure was associated with a lower pain score by greater
than 1 point compared to primary total knee procedure
(AD -1.03; 95% CI -1.68, − 0.38) (Table 4).
Discussion
Multi-modal pain protocols following THA/TKA have
become the standard of care [2–5]. Oral medications,
with or without the use of regional and local anesthesia
Table 3 Pain failure and highest pain score in first 48 h post-op
Pain Failure? Mean
Highest
Pain
Score
Pain Score≤ 5 Pain Score > 5
Pain Level
In PACU – – 1.8 ± 1.8
0–6 h 146 (61.6) 91 (38.4) 4.3 ± 3.1
6–12 h 117 (64.3) 65 (35.7) 4.2 ± 3.1
12–24 h 59 (28.6) 147 (71.4) 6.4 ± 2.8
24–28 h 44 (20.5) 171 (79.5) 6.8 ± 2.6
Highest Pain 0-48 h 32 (13.5) 205 (86.5) 7.5 ± 2.2
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Table 4 Bivariate and multivariable linear regression models of the highest pain score in the first 48 h post-op
Highest Pain Score (0-48 h)
Bivariate Multivariable
AD (95%CI) p-value AD (95% CI) p-value
Gender
Male 0 – – –
Female 0.29 (−0.32, 0.91) 0.35 – –
Age -0.05 (− 0.07, − 0.02) 0.0002 -0.05 (− 0.07, − 0.02) 0.001
BMI 0.03 (0.01, 0.05) 0.02 0.01 (− 0.01, 0.04) 0.28
Side
Right 0 – – –
Left 0.22 (− 0.36, 0.80) 0.45 – –
Surgery
Primary Total Knee 0 – 0 –
Revision Total Knee −0.82 (−1.89, 0.25) 0.13 −0.87 (− 1.92, 0.18) 0.12
Primary Total Hip −0.83 (−1.48, − 0.19) 0.01 − 1.03 (− 1.68, − 0.38) 0.002
Revision Total Hip −0.01 (− 1.17, 1.15) 0.99 − 0.23 (− 1.43, 0.98) 0.71
Bilateral Knee 2.12 (− 0.89, 5.14) 0.17 2.27 (− 0.56, 5.11) 0.12
PCA
Yes 0.70 (0.01, 1.39) 0.05 0.40 (−0.32, 1.12) 0.28
No 0 – 0 –
Type of Block
None 0 – – –
Spinal/Epidural 0.69 (−0.20, 1.59) 0.13 – –
Femoral/Intraarticular 0.94 (−0.39, 2.27) 0.17 – –
Smoker
Yes 0.39 (−0.32, 1.10) 0.28 – –
No 0 – – –
Alcohol
Yes 0.28 (−0.46, 1.01) 0.46 – –
No 0 – – –
Hx Pain Management
Yes 0.69 (0.12, 1.27) 0.02 0.82 (−3.30, 4.94) 0.70
No 0 – 0 –
Home Pain Meds
None 0 – 0 –
Opioids 0.97 (0.34, 1.59) 0.002 0.09 (−4.06, 4.24) 0.97
Neurontin/Lyrica 0.52 (−0.93, 2.00) 0.49 −0.62 (− 4.98, 3.74) 0.78
Other −0.38 (−1.46, 0.71) 0.49 −1.07 (−5.08, 2.94) 0.60
Steroids
Yes 0.23 (−0.76, 1.22) 0.65 – –
No 0 – – –
Antidepressants
Yes 0.50 (−0.45, 1.44) 0.30 – –
No 0 – – –
Diabetes
Yes −0.02 (−0.65, 0.61) 0.94 – –
No 0 – – –
Ref = 0
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make up a plethora of pain regimens, and recently lipo-
somal bupivacaine became an important component
allowing for improved pain relief for up to 72 h [12].
Several studies reported lower pain scores as the benefits
of extended release bupivacaine exhibited promising re-
sults [12–16]. However, as usage grew, results of several
randomized trials, made even devoted users skeptical as
the data exhibited non-superior results when compared
to other modalities [7–10]. As a result, many ortho-
paedic surgeons have moved away from use of liposomal
bupivacaine citing high cost for no presumed benefit [9].
To our knowledge, however, none of these studies per-
formed sub-cohort analyses to determine if any risk factors
for liposomal bupivacaine resistance (LBR); anecdotally (and
exhibited in the literature), some patients do experience a
clear benefit, and this formulates the base hypothesis for this
study.
Our current study investigated the efficacy of pain
control after liposomal bupivacaine injection following
TKA/THA at various time intervals in order to ascertain
risk factors leading to resistance of liposomal bupiva-
caine. Results from our study demonstrated that a total
of 86% of the 237 patients included had pain failure at
least once during the first 48 h. Not surprisingly,
smokers, younger patients less than 64 years old, and pa-
tients with prior opioid use, experienced significantly
higher rates of pain failure at various time intervals
(Table 2) [17–20]. Previous literature has demonstrated
that older patients tend to use less opioids than younger
patients which may result from changes in metabolism
and clearance of opioid drugs with increased age [17–19].
Recent literature on how age influences post operative
pain following TKA or THA is contradictory and has
demonstrated no difference in pain in some studies, while
others show younger patients have more pain [21, 22]. In
addition, prior studies have demonstrated that smoking
has been associated with high pain scores when compared
with non-smoker counterparts [20]. Smoking has shown
associated with changes in levels of neuropeptides that
play a role in chronic pain, and patients who smoke typic-
ally have lower plasma beta-endorphin levels [23, 24].
Lastly, the induction of cytochrome P-450 isoenzymes by
tobacco smoke can increase the metabolism of opioids
thus leading to inadequate pain control [25, 26].
This study does have some limitations. Power calcula-
tion at 0.80 and alpha of 0.05, yielded a R-squared coeffi-
cient of 87.5% indicating significance for the regression
analysis performed. At a power of 0.90, however, R-
squared coefficient fell to 52.3%, offering a less reliable
significance at a higher power. However, with a signifi-
cant R-squared at a power of 0.80, the authors consid-
ered the statistical significance appropriately interpreted
for the conclusions found in this study. Another limita-
tion of this study is a lack of control group. When
examining our data, we found that our baseline pain
scores were in line with historical controls; therefore, a
control group was assessed. In addition, retrospective
analysis of a registry may have led to potential inherent
bias; however, the goal of this study was not to demon-
strate superiority but rather identify risk factors for fail-
ure of pain management with liposomal bupivacaine.
Lastly, there were select patients who were provided
with PCA, regional block, or spinal anesthesia, which
may influence pain scores for patients receiving liposo-
mal bupivacaine, but this was also taken into consider-
ation in our statistical analysis.
Conclusion
Liposomal bupivacaine has been shown to be efficacious
in pain control management following primary and revi-
sion arthroplasties. However, our study demonstrated
that younger age less than 64, and a history of smoking,
pain management, and opioid use, led to failed pain
management after use of liposomal bupivacaine as part
of a multi-modal pain regimen. Future studies should
use these criteria as exclusion criteria when using liposo-
mal bupivacaine or initiating any randomized trials re-
garding efficacy.
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